The most recent trading session ended with Viking Therapeutics, Inc. (VKTX) standing at $29.28, reflecting a +1.14% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily gain of 1.77%. Elsewhere, the Dow saw an upswing of 1.42%, while the tech-heavy Nasdaq appreciated by 2.28%.The the stock of company has fallen by 15.03% in the past month, lagging the Medical sector's loss of 1.17% and the S&P 500's loss of 5.73%.Analysts and investors alike will be keeping a ...

Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024, but, unfortunately, they have been southbound since then. Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain unashamedly bullish on the company.Viking's average price target of $99.29 (according to analysts tracked by Yahoo! Finance) implies an up ...

Viking Therapeutics (VKTX -0.07%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.While the optimism surrounding the drug made Viking's stock a hot buy early last year, things have drastically cooled over the past six months during which it has plummeted more than 50%. As a result, the stock is now down 65% fr ...

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as the end of Q1 approaches [1] - It suggests that investors may consider joining a platform called Out Fox The Street for insights on positioning in these stocks [1] Group 2 - There is a mention of a potential beneficial long position in VKTX that may be initiated within the next 72 hours [2] - The article emphasizes that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned [2] Group 3 - The information provided is intended for informational purposes only and does not constitute a solicitation to buy or sell securities [3] - It highlights the importance of conducting personal research or consulting a financial advisor before making investment decisions [3] Group 4 - The article notes that past performance is not indicative of future results and that no specific investment recommendations are being made [4] - It clarifies that the views expressed may not represent those of Seeking Alpha as a whole and that the analysts involved may not be licensed or certified [4]

Shares of Viking Therapeutics (VKTX) gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral and subcutaneous (SC) formulations of its obesity drug.Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and SC versions for treatin ...

Viking Therapeutics (VKTX) signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC) formulations of its obesity drug VK2735.Per the terms, Viking has secured dedicated manufacturing capacity to support the large-scale production of VK2735. The deal includes an annual supply commitment for multiple metric tons of the active pharmaceutical ingredient (API) behind VK2735, along with fill/finish cap ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation. BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading ...

 Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical IngredientSecures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe SupplyProvides Annual Capacity of Over 1 Billion Oral TabletsViking to Make Prepayments Totaling $150 Million Between 2025-2028SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company ...